Cellectar Biosciences Reported Positive Trial Results
The Phase 2 study of iopofosine I 131 shows promise for patients with Waldenström Macroglobulinemia.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies can safely accelerate the approval process for new cancer treatments?
Cellectar Biosciences released data from a subset analysis of its Phase 2 CLOVER WaM clinical trial. The findings highlight significant response rates for patients treated with iopofosine I 131 after failing BTK inhibitor therapy.
Why it matters
The study offers a potential new treatment pathway for patients who are refractory or resistant to standard BTK inhibitor therapies. Finding effective options for these resistant cases remains a critical need for those diagnosed with this rare cancer.
The study reported a major response rate of 79.2% and an overall response rate of 87.5% in the analyzed subset. The duration of response for these patients exceeded 16 months.
The players
Cellectar Biosciences
This is a biopharmaceutical company headquartered in Florham Park, New Jersey, focused on developing targeted cancer therapies.
International Workshop for Waldenström Macroglobulinemia
This is a specialized medical assembly scheduled to take place in Palm Springs, California.
The details
Patients in the analyzed group received iopofosine I 131 as an immediate follow-up to BTK inhibitor therapy. Cellectar Biosciences will present the full findings in a poster presentation titled Iopofosine I 131 After BTK Inhibitors in Waldenström Macroglobulinemia.
Timeline
September 29, 2026: Cellectar Biosciences announced the clinical trial data.
October 14-16, 2026: International Workshop for Waldenström Macroglobulinemia occurs.
October 15, 2026: Poster presentation takes place at 4:00 PM in Palm Springs, California.
Early 2027: Planned Phase 3 clinical trial dosing begins.
1H 2027: Planned submission for U.S. accelerated market approval.
The Big Picture
This announcement follows a pattern set by other oncology drug development programs that utilize positive interim results to initiate Phase 3 confirmatory trials. It marks an advancement in the broader trajectory of investigating targeted radiopharmaceuticals for hematologic malignancies.
This data provides a potential future treatment option for patients who have exhausted standard therapy lines, offering hope for prolonged response times. Patients should consult their oncologists regarding the availability of clinical trials as these new options move toward regulatory review.
The takeaway
The successful subset analysis demonstrates that iopofosine I 131 may serve as a viable post-BTK inhibitor treatment. The company is now focused on the rigorous testing required to secure regulatory approval through a future Phase 3 confirmatory study.
What happens next
Cellectar Biosciences plans to begin dosing patients for a Phase 3 confirmatory trial in early 2027, followed by a submission for U.S. accelerated market approval in the first half of 2027.
Further reading
For more context on ongoing breakthroughs in oncology, visit the Cancer section.
More information
For more details on the company's research, visit the Cellectar Biosciences company information.
Live Poll
Do you trust that pharmaceutical companies can safely accelerate the approval process for new cancer treatments?
